S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NASDAQ:IDRA

Idera Pharmaceuticals - IDRA Stock Forecast, Price & News

$0.37
-0.02 (-5.07%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.36
$0.41
50-Day Range
$0.37
$0.53
52-Week Range
$0.30
$1.06
Volume
143,693 shs
Average Volume
503,481 shs
Market Capitalization
$19.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDRA stock logo

About Idera Pharmaceuticals (NASDAQ:IDRA) Stock

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends
Idera Pharmaceuticals (NASDAQ:IDRA) Now Covered by StockNews.com
Why Are Idera Pharmaceuticals Shares Soaring Today
Idera Pharmaceuticals Announces Tilsotolimod Updates
IDRA Nov 2021 3.000 call
Idera Pharmaceuticals Announces Corporate Updates
Why Idera Pharmaceuticals Stock Is Crashing Today
See More Headlines
Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Company Calendar

Last Earnings
8/09/2022
Today
9/30/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Profitability

Net Income
$98.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.45 million
Cash Flow
$1.78 per share
Book Value
$0.56 per share

Miscellaneous

Free Float
50,371,000
Market Cap
$19.87 million
Optionable
Optionable
Beta
1.41

Social Links


Key Executives

  • Mr. Vincent J. Milano (Age 58)
    Pres, CEO & Director
    Comp: $794.24k
  • Mr. John J. Kirby CPAMr. John J. Kirby CPA (Age 50)
    Sr. VP & CFO
    Comp: $477.41k
  • Mr. Daniel B. SolandMr. Daniel B. Soland (Age 66)
    Sr. VP & COO
    Comp: $552.83k
  • Mr. Bryant David LimMr. Bryant David Lim (Age 51)
    Sr. VP, Chief Bus. Officer & Gen. Counsel
    Comp: $480.96k
  • Ms. Jill Conwell
    Sr. VP of Investor Relations & Corp. Communications
  • Ms. Elizabeth Eberhardt
    Sr. VP of Product Leadership
  • Dr. Shah Rahimian M.D.
    Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B (Age 67)
    M.B., Advisor
  • Dr. Sudhir Agrawal D.Phil. (Age 68)
    DPHIL, F.R.S.C., Scientific Advisor
  • Mr. Louis J. Arcudi III (Age 61)
    M.B.A., MBA, Adviser













IDRA Stock - Frequently Asked Questions

How have IDRA shares performed in 2022?

Idera Pharmaceuticals' stock was trading at $0.57 at the beginning of 2022. Since then, IDRA stock has decreased by 34.3% and is now trading at $0.3747.
View the best growth stocks for 2022 here
.

When is Idera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our IDRA earnings forecast
.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.10) earnings per share for the quarter.

When did Idera Pharmaceuticals' stock split?

Idera Pharmaceuticals shares reverse split on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?
What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $0.37.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals (NASDAQ:IDRA) has a market capitalization of $19.88 million and generates $1.45 million in revenue each year. The biotechnology company earns $98.09 million in net income (profit) each year or ($0.37) on an earnings per share basis.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The biotechnology company can be reached via phone at (484) 348-1600, via email at jconwell@iderapharma.com, or via fax at 617-679-5592.

This page (NASDAQ:IDRA) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.